{"id":60583,"date":"2026-03-23T15:58:50","date_gmt":"2026-03-23T07:58:50","guid":{"rendered":"https:\/\/flcube.com\/?p=60583"},"modified":"2026-03-23T15:58:50","modified_gmt":"2026-03-23T07:58:50","slug":"hansoh-pharma-wins-nmpa-approval-for-two-category-1-drugs-hs-20152-and-hs-10587-enter-clinical-trials-in-rare-disease-and-oncology","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=60583","title":{"rendered":"Hansoh Pharma Wins NMPA Approval for Two Category 1 Drugs \u2013 HS\u201120152 and HS\u201110587 Enter Clinical Trials in Rare Disease and Oncology"},"content":{"rendered":"\n<p><strong>Hansoh Pharmaceutical Group Company Limited<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/3692:HKG\">HKG: 3692<\/a>) announced that <strong>two Category 1 innovative drugs<\/strong> have received <strong>NMPA clinical trial approval<\/strong> \u2013 expanding its pipeline into <strong>rare hematologic disease<\/strong> with <strong>HS\u201120152 for paroxysmal nocturnal hemoglobinuria (PNH)<\/strong> and <strong>precision oncology<\/strong> with <strong>HS\u201110587 for MTAP\u2011deficient advanced solid tumors<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-milestone-dual-ind-approvals\">Regulatory Milestone \u2013 Dual IND Approvals<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Asset<\/th><th>Indication<\/th><th>Therapeutic Area<\/th><th>Development Origin<\/th><\/tr><\/thead><tbody><tr><td><strong>HS\u201120152<\/strong><\/td><td><strong>Paroxysmal Nocturnal Hemoglobinuria (PNH)<\/strong><\/td><td>Rare hematologic disease<\/td><td>Hansoh self\u2011developed<\/td><\/tr><tr><td><strong>HS\u201110587<\/strong><\/td><td><strong>Advanced solid tumors with MTAP deficiency<\/strong><\/td><td>Precision oncology (tumor\u2011agnostic)<\/td><td>Hansoh self\u2011developed<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Regulatory Status:<\/strong> Both Category 1 innovative drugs (highest NMPA classification for novel mechanisms)<\/li>\n\n\n\n<li><strong>Approval Date:<\/strong> March 23, 2026<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-product-profile-hs-20152-pnh\">Product Profile \u2013 HS\u201120152 (PNH)<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Target Indication:<\/strong> <strong>Paroxysmal Nocturnal Hemoglobinuria (PNH)<\/strong><\/li>\n\n\n\n<li><strong>Disease Context:<\/strong> Rare, acquired hematologic disorder characterized by complement\u2011mediated hemolysis, thrombosis risk, and bone marrow failure<\/li>\n\n\n\n<li><strong>Current Standard of Care:<\/strong> C5 inhibitors (eculizumab, ravulizumab); oral complement inhibitors (iptacopan) recently approved<\/li>\n\n\n\n<li><strong>HS\u201120152 Positioning:<\/strong> Next\u2011generation complement pathway modulation or novel mechanism for PNH treatment<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-product-profile-hs-10587-mtap-deficient-tumors\">Product Profile \u2013 HS\u201110587 (MTAP\u2011Deficient Tumors)<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Target Indication:<\/strong> <strong>Advanced solid tumors with MTAP (methylthioadenosine phosphorylase) deficiency<\/strong><\/li>\n\n\n\n<li><strong>Biomarker:<\/strong> <strong>MTAP deficiency<\/strong> \u2013 tumor\u2011agnostic genetic alteration present in ~15% of solid tumors (pancreatic cancer, glioblastoma, mesothelioma, lung cancer)<\/li>\n\n\n\n<li><strong>Mechanism Rationale:<\/strong> MTAP deficiency creates <strong>methylthioadenosine (MTA) accumulation<\/strong> and <strong>PRMT5 synthetic lethality<\/strong> \u2013 emerging precision oncology target<\/li>\n\n\n\n<li><strong>Competitive Landscape:<\/strong> MRTX1719 (Mirati), AMG 193 (Amgen), TNG908 (Tango) in clinical development; no approved MTAP\u2011targeted therapies globally<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-implications\">Strategic Implications<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Dimension<\/th><th>HS\u201120152 (PNH)<\/th><th>HS\u201110587 (MTAP)<\/th><\/tr><\/thead><tbody><tr><td><strong>Market Strategy<\/strong><\/td><td>Rare disease premium pricing; orphan drug incentives<\/td><td>Tumor\u2011agnostic precision oncology; biomarker\u2011driven development<\/td><\/tr><tr><td><strong>Competitive Position<\/strong><\/td><td>Follow\u2011on to established complement inhibitors; differentiation required<\/td><td>First\u2011in\u2011class potential in MTAP synthetic lethality<\/td><\/tr><tr><td><strong>Clinical Development<\/strong><\/td><td>Smaller, faster trials (rare disease); potential for China\u2011first approval<\/td><td>Requires biomarker screening infrastructure; basket trial design<\/td><\/tr><tr><td><strong>Global Potential<\/strong><\/td><td>Ex\u2011China licensing opportunity upon Phase II data<\/td><td>High\u2011value partnership target given tumor\u2011agnostic mechanism<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-impact-amp-outlook\">Market Impact &amp; Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Hansoh Innovation Pipeline:<\/strong> Two simultaneous Category 1 IND approvals demonstrate <strong>R&amp;D productivity<\/strong> beyond established generics\/biosimilars business; rare disease + precision oncology combination aligns with industry high\u2011value therapeutic area trends.<\/li>\n\n\n\n<li><strong>PNH Market Dynamics:<\/strong> Global PNH market <strong>US$3\u20114 billion<\/strong> annually; C5 inhibitors dominate with high annual costs (US$400,000\u2011600,000); HS\u201120152 must demonstrate <strong>superior efficacy, oral convenience, or lower cost<\/strong> to capture market share; China represents ~8,000\u201110,000 PNH patients with growing diagnosis rates.<\/li>\n\n\n\n<li><strong>MTAP Synthetic Lethality Frontier:<\/strong> MTAP deficiency creates <strong>PRMT5 dependency<\/strong> \u2013 validated synthetic lethal target; HS\u201110587 enters competitive but uncrowded field; success would validate Hansoh&#8217;s <strong>early\u2011stage discovery capabilities<\/strong> and attract global partnership interest (estimated deal value <strong>US$200\u2011400 million<\/strong> for ex\u2011China rights upon Phase I data).<\/li>\n\n\n\n<li><strong>Clinical Development Timelines:<\/strong> Phase I safety\/PK for both assets expected <strong>H2 2026<\/strong>; HS\u201120152 Phase II proof\u2011of\u2011concept <strong>2027\u20112028<\/strong> given smaller PNH patient population; HS\u201110587 biomarker\u2011enriched Phase II <strong>2028\u20112029<\/strong> requiring MTAP screening infrastructure development.<\/li>\n\n\n\n<li><strong>Capital Efficiency:<\/strong> Self\u2011developed assets (vs. in\u2011licensing) preserve margin potential; Hansoh&#8217;s <strong>RMB2+ billion annual R&amp;D investment<\/strong> supports multiple parallel innovative programs; these INDs validate platform beyond fast\u2011follower strategies.<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding clinical development timelines, mechanism validation, and commercial expectations for HS\u201120152 and HS\u201110587. Actual results may differ due to risks including safety findings in first\u2011in\u2011human studies, competitive dynamics in PNH and MTAP\u2011targeted therapy landscapes, and manufacturing scale\u2011up challenges.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/2026032300078_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 2026032300078_c.\"><\/object><a id=\"wp-block-file--media-c66744f8-6abc-4349-b5ca-287006be5665\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/2026032300078_c.pdf\">2026032300078_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/2026032300078_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-c66744f8-6abc-4349-b5ca-287006be5665\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Hansoh Pharmaceutical Group Company Limited (HKG: 3692) announced that two Category 1 innovative drugs have&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[16,62,363,1182,24],"class_list":["post-60583","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-cancer","tag-clinical-trial-approval-initiation","tag-hansoh-pharmaceutical","tag-hkg-3692","tag-rare-orphan-disease-drugs"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Hansoh Pharma Wins NMPA Approval for Two Category 1 Drugs \u2013 HS\u201120152 and HS\u201110587 Enter Clinical Trials in Rare Disease and Oncology - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Hansoh Pharmaceutical Group Company Limited (HKG: 3692) announced that two Category 1 innovative drugs have received NMPA clinical trial approval \u2013 expanding its pipeline into rare hematologic disease with HS\u201120152 for paroxysmal nocturnal hemoglobinuria (PNH) and precision oncology with HS\u201110587 for MTAP\u2011deficient advanced solid tumors.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=60583\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Hansoh Pharma Wins NMPA Approval for Two Category 1 Drugs \u2013 HS\u201120152 and HS\u201110587 Enter Clinical Trials in Rare Disease and Oncology\" \/>\n<meta property=\"og:description\" content=\"Hansoh Pharmaceutical Group Company Limited (HKG: 3692) announced that two Category 1 innovative drugs have received NMPA clinical trial approval \u2013 expanding its pipeline into rare hematologic disease with HS\u201120152 for paroxysmal nocturnal hemoglobinuria (PNH) and precision oncology with HS\u201110587 for MTAP\u2011deficient advanced solid tumors.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=60583\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-03-23T07:58:50+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=60583#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=60583\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Hansoh Pharma Wins NMPA Approval for Two Category 1 Drugs \u2013 HS\u201120152 and HS\u201110587 Enter Clinical Trials in Rare Disease and Oncology\",\"datePublished\":\"2026-03-23T07:58:50+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=60583\"},\"wordCount\":556,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Cancer\",\"Clinical trial approval \\\/ initiation\",\"Hansoh Pharmaceutical\",\"HKG: 3692\",\"Rare \\\/ orphan disease drugs\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=60583#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=60583\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=60583\",\"name\":\"Hansoh Pharma Wins NMPA Approval for Two Category 1 Drugs \u2013 HS\u201120152 and HS\u201110587 Enter Clinical Trials in Rare Disease and Oncology - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-03-23T07:58:50+00:00\",\"description\":\"Hansoh Pharmaceutical Group Company Limited (HKG: 3692) announced that two Category 1 innovative drugs have received NMPA clinical trial approval \u2013 expanding its pipeline into rare hematologic disease with HS\u201120152 for paroxysmal nocturnal hemoglobinuria (PNH) and precision oncology with HS\u201110587 for MTAP\u2011deficient advanced solid tumors.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=60583#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=60583\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=60583#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Hansoh Pharma Wins NMPA Approval for Two Category 1 Drugs \u2013 HS\u201120152 and HS\u201110587 Enter Clinical Trials in Rare Disease and Oncology\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Hansoh Pharma Wins NMPA Approval for Two Category 1 Drugs \u2013 HS\u201120152 and HS\u201110587 Enter Clinical Trials in Rare Disease and Oncology - Insight, China&#039;s Pharmaceutical Industry","description":"Hansoh Pharmaceutical Group Company Limited (HKG: 3692) announced that two Category 1 innovative drugs have received NMPA clinical trial approval \u2013 expanding its pipeline into rare hematologic disease with HS\u201120152 for paroxysmal nocturnal hemoglobinuria (PNH) and precision oncology with HS\u201110587 for MTAP\u2011deficient advanced solid tumors.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=60583","og_locale":"en_US","og_type":"article","og_title":"Hansoh Pharma Wins NMPA Approval for Two Category 1 Drugs \u2013 HS\u201120152 and HS\u201110587 Enter Clinical Trials in Rare Disease and Oncology","og_description":"Hansoh Pharmaceutical Group Company Limited (HKG: 3692) announced that two Category 1 innovative drugs have received NMPA clinical trial approval \u2013 expanding its pipeline into rare hematologic disease with HS\u201120152 for paroxysmal nocturnal hemoglobinuria (PNH) and precision oncology with HS\u201110587 for MTAP\u2011deficient advanced solid tumors.","og_url":"https:\/\/flcube.com\/?p=60583","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-03-23T07:58:50+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=60583#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=60583"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Hansoh Pharma Wins NMPA Approval for Two Category 1 Drugs \u2013 HS\u201120152 and HS\u201110587 Enter Clinical Trials in Rare Disease and Oncology","datePublished":"2026-03-23T07:58:50+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=60583"},"wordCount":556,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Cancer","Clinical trial approval \/ initiation","Hansoh Pharmaceutical","HKG: 3692","Rare \/ orphan disease drugs"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=60583#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=60583","url":"https:\/\/flcube.com\/?p=60583","name":"Hansoh Pharma Wins NMPA Approval for Two Category 1 Drugs \u2013 HS\u201120152 and HS\u201110587 Enter Clinical Trials in Rare Disease and Oncology - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-03-23T07:58:50+00:00","description":"Hansoh Pharmaceutical Group Company Limited (HKG: 3692) announced that two Category 1 innovative drugs have received NMPA clinical trial approval \u2013 expanding its pipeline into rare hematologic disease with HS\u201120152 for paroxysmal nocturnal hemoglobinuria (PNH) and precision oncology with HS\u201110587 for MTAP\u2011deficient advanced solid tumors.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=60583#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=60583"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=60583#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Hansoh Pharma Wins NMPA Approval for Two Category 1 Drugs \u2013 HS\u201120152 and HS\u201110587 Enter Clinical Trials in Rare Disease and Oncology"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/60583","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=60583"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/60583\/revisions"}],"predecessor-version":[{"id":60585,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/60583\/revisions\/60585"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=60583"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=60583"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=60583"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}